Facilitating a Multi-Institutional Enterprise

促进多机构企业

• 批准号: 10172700
• 负责人: Steven Allan Soper
• 金额: $ 26.65万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-16 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10172700
• 关键词: Adopted; Advisory Committees; Affect; Annual Reports; Biological; Biological Assay; Biotechnology; Blood Circulation; Cells; Clinical; Collaborations; Commercial Sectors; Committee Members; Communities; Complex; DNA; Data; Development; Devices; Disease; Educational workshop; Epigenetic Process; Evolution; Flow Cytometry; Future; Generations; Goals; Grant; Human Resources; Infrastructure; Injections; Institution; Interdisciplinary Study; Leadership; Length; Liquid substance; Microscopy; Mission; Modeling; Modification; Molds; Molecular; Molecular Analysis; Molecular Biology; NCI Scholars Program; Nanotechnology; National Institute of Biomedical Imaging and Bioengineering; Nature; Operating System; Outcome; Output; Participant; Plastics; Private Sector; Privatization; Procedures; Process; Proteins; RNA; Records; Reporting; Research; Research Personnel; Research Training; Resolution; Resources; Running; Schedule; Seasons; Secure; Services; Site; Surface; Surveys; System; Talents; Technology; Testing; Time; Training; Training Programs; Translating; United States National Institutes of Health; Update; Vision; Work; base; cell free DNA; design; experience; extracellular vesicles; innovation; instructor; instrumentation; interest; liquid biopsy; meetings; member; multidisciplinary; nature center; new technology; organizational structure; precision medicine; program dissemination; programs; prospective; recruit; response; single molecule; skills; success; tool; visiting scholar; web site

Title: Biotechnology Resource Center of BioModular Multi-scale Systems (CBM2) for Precision Medicine Administration: Facilitating a Multi-Institutional Enterprise Abstract/Summary The Biotechnology Research Center of BioModular Multi-scale Systems (CBM2) for Precision Medicine, which is seeking to continue its important mission through this competitive renewal application, has outlined an aggressive and highly innovative research program that will generate new technology platforms for the analysis of markers secured from circulation as part of the Liquid Biopsy initiative. These markers include rare biological cells, cell free DNA, and extracellular vesicles as well as the molecular cargo they carry (DNAs, RNAs, and proteins). In its active rendition (2015-2020), CBM2 generated new platforms for the isolation of these liquid biopsy markers and amplification-based molecular assays of their cargo that can be used to guide clinical decisions for a number of important disease states (i.e., Precision Medicine). Unique to this competitive renewal is the evolution of innovative tools to enable the analysis of the liquid biopsy's molecular cargo without requiring amplification that will provide unique opportunities, such as the analysis of epigenetic modifications in DNAs and RNAs. Our platform technology is innovative in that the isolation steps will be integrated to the molecular analysis steps to form fully automated mixed-scale (micro- and nanotechnologies) and modular fluidic systems. The fluidic systems will be populated with task specific modules produced from the expiring P41 as well as innovative ones evolving from the TR&Ds in this competitive renewal. All modules are manufactured in plastics using injection compression molding. The modules can also be used as standalone units to facilitate dissemination. The lofty goals envisioned by CBM2 will be realized through an accomplished multidisciplinary team of researchers across several institutions that possess complementary skill sets. The Administrative Core of the Center will seek to coordinate activities between the Center's researchers to aggressively move the research program forward in a timely manner to provide compelling outputs that will not only provide unique opportunities for the Center's Collaborative and Service Projects, but the biomedical community as a whole. The Center's leadership team is seasoned with extensive experiences in managing large research organizations that have demonstrated success within the research community as well as generating compelling training programs for a variety of audiences with an interest in liquid biopsies and mixed-scale fabrication. The Leadership Team will coordinate the research efforts of the Center with its Collaborative Projects to allow for application driven development of the proposed technologies. The Center is well versed in transitioning its technologies into the commercial sector to facilitate dissemination that will increase Center visibility through Service Projects. The system design approach adopted by the Center (modular format) will facilitate the generation of integrated fluidic systems for automating complex assays. Collaborative and Service Projects will also evolve from the Center through the engaging Training and Dissemination Program including a robust website and extensive networks provided by the Leadership Team as well as an active Visiting Scholar's Program.

标题：生物技术资源中心生物模块化多尺度系统（CBM2）精密医学 管理：促进多机构企业 摘要/摘要 生物技术研究中心生物模块多尺度系统（CBM2），用于精密医学，该研究中心 正在寻求通过此竞争性更新应用继续其重要使命，概述了 积极进取和高度创新的研究计划，该计划将生成新的技术平台以进行分析 作为液体活检倡议的一部分，无法循环的标记物。这些标记包括稀有生物学 细胞，无细胞DNA和细胞外囊泡以及它们携带的分子货物（DNA，RNA和 蛋白质）。在其主动演绎（2015-2020）中，CBM2生成了用于隔离这些液体的新平台 活检标记和基于扩增的分子测定，可用于指导临床 许多重要疾病状态（即精密医学）的决定。这种竞争性更新独有 是创新工具的演变，可以分析液体活检的分子货物而无需 放大将提供独特的机会，例如对DNA和 RNA。我们的平台技术具有创新性，因为隔离步骤将集成到分子分析 形成全自动的混合尺度（微技术和纳米技术）和模块化流体系统的步骤。流体 系统将带有从到期的P41和创新的系统中产生的特定任务模块 从这种竞争性更新中的TR＆D演变。所有模块均使用注射塑料制造 压缩成型。这些模块也可以用作独立单元，以促进传播。 CBM2设想的崇高目标将通过成就的多学科团队实现 多个具有互补技能的机构的研究人员。行政核心 中心将寻求协调中心研究人员之间的活动，以积极地进行研究 及时向前推进计划，以提供引人注目的输出，不仅会提供独特的机会 对于中心的合作和服务项目，但整个生物医学界。中心的 领导团队在管理大型研究组织方面经验丰富的经验 在研究社区中取得了成功，并为 对液体活检和混合规模制造感兴趣的观众种类繁多。领导团队将 协调中心的研究工作与其协作项目，以允许应用程序驱动 拟议技术的开发。该中心精通将其技术过渡到 商业部门促进传播将通过服务项目提高中心的可见性。这 中心采用的系统设计方法（模块化格式）将有助于综合流体的产生 自动化复杂测定的系统。协作和服务项目也将从中心发展 通过引人入胜的培训和传播计划，包括强大的网站和广泛的网络 由领导团队以及积极的访问学者计划提供。